Despite the use of guideline-directed medical therapy (GDMT), many heart failure (HF) patients may experience worsening symptoms and disease progression. There is now an FDA-approved device that works with GDMT and uses the baroreflex to improve HF-related physiological effects and clinical consequences. Tune in to keep up with baroreflex activation therapy, its mechanism of action, and the associated improved patient outcomes.
Direct from the Heart Failure Clinic: Novel Device Therapy for Patients with HFrEF
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Marat Fudim, MD, MHS
Assistant Professor of Medicine
Duke University
Durham, NCConsulting Fees: CVRx, Inc.
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Howard Green has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Katie Sheridan, PhD, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Discuss heart failure-related morbidity and mortality outcomes despite the use of guideline-directed medical therapy
- Describe the mechanism of action of baroreflex activation therapy (BAT)
- Review the latest clinical data on the use of BAT in patients with heart failure, highlighting patient profile and selection
Target Audience
This activity is designed to meet the educational needs of cardiologists, cardiology advanced practice professionals, and other healthcare professionals who have an interest in treating heart failure.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Commercial Support
This activity is supported by an independent educational grant from CVRx, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE
Optimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
0.25 creditsJürgen Floege, MD
Jonathan Barratt, PhD
Raymond Townsend, MD
Melissa Magwire, RN, MSN
Michael Weber, MD
Christina Economides, MD
Brian Howard, MD
David N. Kenigsberg, MD, FACC
Kelly Chenlei Li, MBBS, FRACP
Paul Bennett, RN, MHSM, PhD, FISN
Thilo Krüger, MD, PhD